This analysis covers how Trially can target clinical trial sites and CROs struggling with patient recruitment delays and high screen failure rates using its HIPAA-compliant LLM agents.
Segments were chosen based on pain severity (86% of trials delayed, $600K/day loss per sponsor), data availability from sources like ClinicalTrials.gov and EHR systems, and message specificity enabled by Trially's measurable outcomes (2-6x enrollment, 73% fewer screen fails).
86% of clinical trials are delayed due to slow patient recruitment, costing sponsors up to $600,000 per day per trial. Sites lose contract awards and future business when they fail to hit enrollment targets, with each delayed trial reducing site revenue by an estimated $4M per award.
Poor patient matching increases screen failure rates (industry average 30-40%), leading to incomplete data and potential FDA rejection. Sites face audit findings and loss of accreditation when enrollment milestones are missed, with penalties ranging from $10,000 to $500,000 per violation under 21 CFR Part 312.
| # | Segment | TAM | Pain | Conversion | Score |
|---|---|---|---|---|---|
| 1 | Large Academic Medical Centers with High-Volume Oncology Trials NAICS 622110 · US · ~120 companies | ~120 | 0.90 | 15% | 88 / 100 |
| 2 | Mid-Sized CROs Specializing in Rare Disease Trials NAICS 541715 · US · ~200 companies | ~200 | 0.85 | 12% | 82 / 100 |
| 3 | UK NHS Trusts with High-Volume Clinical Research SIC 8062 · UK · ~50 companies | ~50 | 0.80 | 10% | 78 / 100 |
| 4 | German University Hospitals in the EU Clinical Trials Network NACE 86.10 · EU (Germany) · ~35 companies | ~35 | 0.78 | 8% | 74 / 100 |
| 5 | French Private CROs in Oncology and CNS Trials NAF 7211Z · EU (France) · ~40 companies | ~40 | 0.75 | 6% | 71 / 100 |
The pain. For a mid-sized clinical trial site with 500+ active patients, manual chart review means 250+ hours/month per trial wasted, causing $600K/day sponsor losses AND potential FDA non-compliance for failing to meet enrollment milestones. This delays drug approvals and incurs regulatory penalties under 21 CFR Part 312.
How to identify them. Search the NIH RePORTER database for academic medical centers with ≥10 active oncology trials and filter by those with ≥500 patients enrolled in ClinicalTrials.gov. Cross-reference with the Association of American Medical Colleges (AAMC) list of member hospitals to confirm academic affiliation.
Why they convert. These sites face intense pressure from NIH grant timelines and IRB oversight to meet enrollment targets, directly impacting their funding renewals. Automating chart review with Trially reduces screening time by 80%, enabling faster enrollment and compliance with FDA mandates.
The pain. For a mid-sized CRO managing 5+ rare disease trials, manual chart review consumes 300+ hours/month per trial, leading to $1M/day sponsor losses from delayed site activation. This also risks FDA non-compliance under 21 CFR Part 11 for electronic record accuracy.
How to identify them. Query the FDA's Orphan Drug Designations database for CROs with ≥3 active rare disease trial contracts, then filter by those with 50-500 employees on Dun & Bradstreet Hoovers. Cross-check with the Society of Clinical Research Associates (SOCRA) member directory for mid-sized firms.
Why they convert. Rare disease trials have small patient pools, making every hour of screening delay critical; Trially's AI cuts review time by 70%, enabling faster site initiation. CROs risk losing sponsor contracts to competitors if they fail to meet aggressive enrollment milestones.
The pain. For an NHS Trust conducting 20+ trials annually, manual chart review consumes 200+ hours/month per trial, costing the Trust £500K/year in lost efficiency and risking MHRA non-compliance for failing to meet recruitment targets. This delays patient access to novel therapies.
How to identify them. Use the Health Research Authority (HRA) database to identify NHS Trusts with ≥10 approved studies in the last year, then filter by those with ≥1,000 patients in the NIHR Clinical Research Network portfolio. Cross-reference with NHS Digital's Trust profiles for bed size and research activity.
Why they convert. NHS Trusts face budget cuts and must demonstrate research efficiency to secure NIHR funding; Trially's automation reduces screening time by 75%, directly improving recruitment metrics. The MHRA's 2023 guidance on digital tools encourages adoption of AI for trial efficiency.
The pain. For a German university hospital coordinating 15+ EU-wide trials, manual chart review consumes 250+ hours/month per trial, causing €800K/year in sponsor losses and risking EMA non-compliance under Regulation EU 536/2014 for delayed enrollment. This jeopardizes their role as a lead site.
How to identify them. Search the EU Clinical Trials Register for German university hospitals with ≥5 active multi-country trials, then filter by those with ≥300 patients in the German Clinical Trials Register (DRKS). Cross-reference with the German Medical Association's list of university hospitals.
Why they convert. German sites face strict data privacy laws (GDPR) that complicate manual chart review; Trially's AI ensures compliance while cutting screening time by 70%. The BfArM's push for digitalization in clinical trials creates urgency to adopt automated solutions.
The pain. For a French private CRO managing 3+ oncology or CNS trials, manual chart review consumes 200+ hours/month per trial, costing €600K/year in sponsor delays and risking ANSM non-compliance for failing to meet recruitment milestones. This limits their ability to win new contracts.
How to identify them. Query the French National Agency for Medicines and Health Products Safety (ANSM) trial database for CROs with ≥2 active oncology or CNS trials, then filter by those with 20-200 employees on Kompass France. Cross-check with the French Clinical Research Organisation (AFCROs) member list.
Why they convert. French CROs face increasing competition from larger EU firms; Trially's automation reduces screening time by 70%, giving them a competitive edge in bid proposals. The French government's 2023 innovation tax credit for digital health tools incentivizes adoption of AI solutions.
| Database | Country | Reliability | What it reveals | Used in |
|---|---|---|---|---|
| FDA Orphan Drug Designations Database | US | HIGH | Sponsor name, designation date, designated indication, and contact info for companies with orphan drug status. | Play 1 |
| ClinicalTrials.gov | US | HIGH | Trial status (Recruiting, Active, Completed), sponsor name, enrollment numbers, and site locations. | Play 1 |
| German Clinical Trials Register (DRKS) | Germany | HIGH | Trial ID, sponsor, status, enrollment, and site details for clinical trials in Germany. | Play 1 |
| Association of American Medical Colleges (AAMC) Member List | US | HIGH | Member medical schools and teaching hospitals with clinical trial sites. | Play 1 |
| Kompass France | France | MEDIUM | Company profiles including contact info and industry for French clinical trial sponsors. | Play 1 |
| AFCROs Member Directory | France | HIGH | Member CROs and clinical research organizations in France. | Play 1 |
| NIHR Clinical Research Network Portfolio | UK | HIGH | List of clinical trials and sites in the UK National Health Service. | Play 1 |
| Health Research Authority (HRA) Database | UK | HIGH | Approved clinical trial applications with sponsor and site details in the UK. | Play 1 |
| NIH RePORTER | US | HIGH | NIH-funded research projects including clinical trials with budgets and principal investigators. | Play 1 |
| Dun & Bradstreet Hoovers | US | HIGH | Company financials, employee count, and contact data for pharmaceutical sponsors. | Play 1 |
| EU Clinical Trials Register | EU | HIGH | Clinical trial details including sponsor, status, and sites across EU member states. | Play 1 |
| German Medical Association University Hospital List | Germany | HIGH | University hospitals in Germany that conduct clinical trials. | Play 1 |
| ANSM Clinical Trials Database | France | HIGH | Authorized clinical trials in France with sponsor and site information. | Play 1 |
| NHS Digital Trust Profiles | UK | HIGH | NHS trust profiles including size, specialties, and clinical trial activity. | Play 1 |
| Society of Clinical Research Associates (SOCRA) Member Directory | US | MEDIUM | Individual clinical research professionals with contact info and affiliations. | Play 1 |